Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) hit a new 52-week high during trading on Friday . The stock traded as high as C$3.41 and last traded at C$3.28, with a volume of 19378 shares traded. The stock had previously closed at C$3.25.
Analyst Ratings Changes
MDP has been the topic of a number of recent analyst reports. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the stock a "speculative buy" rating in a research note on Monday, September 30th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday. Finally, Raymond James raised shares of Medexus Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the company from C$3.00 to C$4.00 in a report on Wednesday, November 20th. Three analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Strong Buy" and an average target price of C$5.25.
View Our Latest Report on MDP
Medexus Pharmaceuticals Stock Performance
The firm has a market capitalization of C$80.95 million, a PE ratio of 66.00 and a beta of 1.96. The firm's 50-day moving average is C$2.58 and its 200 day moving average is C$2.40.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Further Reading
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
